SCHEMBL2228000

SCHEMBL2228000

O=C(c1ccc2c(Cl)c3c(nc2c1)CCCC3)N1CCCCC1

nearest known ligand 0.81

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.80
ALDH1A1 P00352 1/20 0.78
HTT P42858 1/20 0.78
KMT2A Q03164 2/20 0.77
SMYD3 Q9H7B4 5/20 0.76
MAPT P10636 8/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
TP53 P04637 3/20 0.72
MEN1 O00255 1/20 0.72
POLB P06746 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2216711 1.00 LMNA (0.80) LMNAALDH1A1HTTKMT2ASMYD3
SCHEMBL18706162 0.91 MAPT (0.79) LMNAALDH1A1HTTKMT2ASMYD3
SCHEMBL18706418 0.90 ALDH1A1 (0.74) LMNAALDH1A1HTTKMT2ASMYD3
SCHEMBL2221189 0.90 LMNA (1.00) LMNAALDH1A1HTTKMT2ASMYD3
SCHEMBL2226175 0.88 ALDH1A1 (0.68) LMNAALDH1A1HTTKMT2ASMYD3
SCHEMBL2227993 0.88 KMT2A (0.67) LMNAALDH1A1HTTKMT2ASMYD3
SCHEMBL2226172 0.88 ALDH1A1 (0.68) LMNAALDH1A1HTTKMT2ASMYD3
SCHEMBL2227997 0.88 KMT2A (0.68) LMNAALDH1A1HTTKMT2ASMYD3
SCHEMBL2226413 0.87 LMNA (0.83) LMNAALDH1A1HTTKMT2ASMYD3
SCHEMBL18706397 0.85 SMYD3 (1.00) ALDH1A1HTTKMT2ASMYD3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US claimed
EP-2523938-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Hybrigenics S.A. (FR) 2012-11-21 EP claimed
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
EP-2523938-B1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2014-09-03 EP disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
EP-2523938-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Hybrigenics S.A. (FR) 2012-11-21 EP disclosed
WO-2011086178-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 LMNA 2583/4885ALDH1A1 3216/4885HTT 915/4885
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 LMNA 2583/4885ALDH1A1 3216/4885HTT 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.